Global Expansion: Q&A with Mike Ryan

Mike Ryan
General manager
Europe
EVERSANA

EVERSANA’s Mike Ryan spoke with Pharmaceutical Executive about the company’s recent expansion into Europe. He discusses opening a new office in Berlin and the overall strategy for the expansion.

Pharmaceutical Executive: What are the challenges you faced expanding into Europe?
Mike Ryan: Expanding into Europe brought the challenge of navigating diverse regulatory, cultural, and operational environments across different countries. However, our footprint already included a strong local team of highly experienced professionals who know the market and have brought invaluable insights into the unique needs of each country. Their expertise helped us adapt centralized processes for local compliance, accelerating our ability to meet region-specific regulatory requirements without compromising our service consistency. With these trusted, market-savvy team members, we are positioned to offer clients commercial solutions that are not only compliant but also tailored to resonate with local healthcare systems and patient populations.

However, it is still complex and challenging to find talent across the globe, and this is one of the biggest reasons we have turned to Germany. The workforce here really reflects the needs of our growing global customers.

PE: What made Berlin an ideal choice for this new location?
Ryan: Germany represents the fourth largest pharmaceutical market in the world and is often the first country our clients will launch products when entering Europe. Berlin combines an innovative life sciences ecosystem, robust healthcare infrastructure, and a central location in Europe, making it a strategic hub for our operations.

Importantly, Berlin also offers access to skilled, experienced professionals who know the European pharmaceutical market and can navigate Germany’s regulatory landscape, as well as being the location of Germany’s Heath Technology Assessment organization. This depth of local expertise allows us to seamlessly support clients across the region, with Berlin as a launchpad for delivering their products to broader European patient populations. Our established team in Berlin enables us to offer clients regionally attuned insights and faster access to this key market.

PE: As EVERSANA builds its global footprint, how is it navigating providing services in areas with different regulations?
Ryan: EVERSANA’s established teams across Europe understand the unique guidelines and market access pathways in each country, allowing us to deliver region-specific solutions that are fully compliant. By aligning global objectives with local regulatory knowledge, we can help clients enter new markets and maintain ongoing compliance. This structure not only builds trust with health authorities but also ensures our clients benefit from insights that enhance their commercial success while meeting all local requirements.

PE: Are there plans to expand further into other regions?
Ryan: Europe is and will continue to be a critical market for growth for EVERSANA. We feel we are well positioned now – just in the past few years – to serve clients with teams in the United Kingdom, Italy, Finland, Ireland, and now Germany. Our approach will continue to be guided by local teams with strong market knowledge and experience, ensuring that each new expansion enables us to deliver solutions that are both globally connected and deeply locally informed. This ensures we provide equitable access to healthcare innovations and supports clients’ global market ambitions.